CHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - PALVELLA THERAPEUTICS INC

Financial Performance:

• Successfully raised $230 million earlier this year, securing funding to support development pipelines through the next few years.
• No specific quarterly revenue, earnings, or margin data disclosed as the company is currently in clinical development; projected to transition to a commercial entity upon NDA approval.
• Peak sales guidance estimates $1–3 billion total ($1 billion for microcystic lymphatic malformations [MLM] and $2 billion for cutaneous venous malformations [CVM]).
• Pricing strategy targets $100,000–$200,000 per patient annually.

Guidance and Future Outlook:

• NDA filing for Cuturin rapamycin was submitted in August; PDUFA date expected in H1 next year (likely end of April).
• Awaiting FDA feedback on potential PDUFA timing by end of October.
• Three active trials ongoing or starting this quarter: Cuturin rapamycin for angiokeratomas, Cuturin pitavastatin for porokeratosis (DAP).
• Plan to launch two new programs later this year (one new indication for Cuturin rapamycin, one new Cuturin product).
• Company transitions to a commercial entity immediately following NDA approval and launch.

Business Segments and Product Lines:

• Lead Asset (Cuturin rapamycin): Topical anhydrous gel platform delivering rapamycin; currently in Phase 3 for MLM, Phase 2 for CVM, and Phase 2 for angiokeratomas.
• Pipeline Expansion: Four disease indications in progress, with a roadmap to six diseases by year-end.
• Second Asset (Cuturin pitavastatin): Phase 2 trial for disseminated superficial actinic porokeratosis (DSAP) starting this quarter.
• Commercial Team: Assembled a world-class leadership group including CMO Ashley Klein (formerly of Dompe), Sales Head Kent Taylor (Insight), and Market Access Head Jen McDonough (Crys Bio).
• Platform Technology: "Cuturin" is a tunable topical gel platform allowing high drug loading and new IP generation for each molecule paired with the vehicle.

Market and Competitive Landscape:

• MLM Market: Addresses ~30,000 patients in the US; currently treated with surgery, sclerotherapy, or ineffective off-label rapamycin.
• CVM Market: Estimated >75,000 patients (double the size of MLM); characterized by bleeding, thrombosis, and functional impairment (e.g., inability to bend joints or wear clothing).
• Competitive Advantage: First-in-class topical formulations for these rare genetic diseases; addresses a clear unmet need where existing therapies offer only temporary relief.
• Payer Engagement: Early discussions with payers indicate positive reception; market is being seeded with disease education and awareness.

Risks and Challenges:

• Regulatory Path: Previously failed to obtain Breakthrough Therapy designation for CVM; will now work with FDA to design the most efficient Phase 3 trial possible, potentially reapplying for Breakthrough status post-design.
• Clinical Execution: Need to finalize Phase 3 trial design for CVM following an imminent End-of-Phase 2 meeting.
• Market Execution: Commercial success relies on successful launch and adoption of high-priced ($100k-$200k) therapy in rare disease markets.

Management Commentary and Tone:

• Tone is confident and forward-looking, emphasizing rapid progression from public transition to commercial readiness.
• Management highlights the "first-in-class" status and the platform's ability to unlock multiple billion-dollar opportunities sequentially.
• Focus is explicitly on accelerating drug delivery to patients rather than pursuing regulatory accolades (like Breakthrough designation) if they delay clinical progress.
• Confident in the commercial team's ability to drive the launch, citing prior success with similar biotech products.

Analyst Questions and Answers:

• Q: Clarification on CVM disease severity vs. cosmetic concerns? A: CVM is a debilitating genetic condition causing functional impairment (pain, bleeding, mobility issues), not merely cosmetic.
• Q: Scope of CVM treatment? A: Drug targets cutaneous manifestations; internal/deep venous malformations are outside the current treatment scope.
• Q: Breakthrough Therapy status? A: Initial application failed; focus is now on FDA interaction to design an efficient Phase 3 trial, with reapplication to be decided based on trial design outcomes.
• Q: Market size comparison between MLM and CVM? A: CVM opportunity is roughly twice the size of MLM due to a larger patient population (75k vs 30k) and slightly larger lesion sizes.
• Q: Future pipeline? A: Two new disease programs will be announced this year, bringing total pipeline to six diseases across three drugs.

Other Key Points:

• Cuturin rapamycin is a specialized anhydrous gel developed after testing 80 prototypes over two years to ensure optimal skin delivery.
• The company aims to be the sole approved treatment for several of these serious, chronic, genetic conditions.
• Commercialization preparations, including disease education and prescriber engagement, are currently underway.